Welcome to our dedicated page for TRXC news (Ticker: TRXC), a resource for investors and traders seeking the latest updates and insights on TRXC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRXC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRXC's position in the market.
TransEnterix, Inc. (NYSE American: TRXC) has received CE Mark approval for its Intelligent Surgical Unit (ISU)™ which enhances the Senhance® Surgical System with machine vision capabilities. This advancement allows access to augmented intelligence in digital laparoscopic procedures across Europe, improving visualization and collaboration in surgeries. Following FDA clearance in the U.S., the ISU is compatible with current Senhance systems and third-party vision technologies. CEO Anthony Fernando emphasizes that this technology is pivotal in transforming surgical practices, further expanding the company's global reach.
TransEnterix, Inc. (NYSE American: TRXC) has completed a registered direct offering of 25 million shares of common stock at $1.25 per share, generating approximately $31.25 million in gross proceeds. The funds will be allocated for general corporate purposes, including working capital. The offering was facilitated by H.C. Wainwright & Co. and is backed by an effective shelf registration statement. The company anticipates its cash resources will support operations through Q4 2022, bolstered by proceeds from this offering and previous warrant exercises.
TransEnterix, a medical device company listed on NYSE American under the ticker TRXC, has announced a registered direct offering of 25,000,000 shares at $1.25 each, aiming to raise $31.25 million. The closing is expected around January 14, 2021, subject to customary conditions. Proceeds will be utilized for general corporate purposes, including working capital. H.C. Wainwright & Co. is the exclusive placement agent for this transaction. The company continues to advance its Senhance® Surgical System, enhancing minimally invasive surgery with digital capabilities.
TransEnterix, Inc. (NYSE American: TRXC) announced a preliminary update for 2020, highlighting significant regulatory achievements and product milestones. The Senhance Surgical System received registration in Russia, and Southern Surgical Hospital in Louisiana agreed to lease one. 2020 revenue is projected at $3.0 - $3.2 million with approximately $17.5 million in cash by year-end. While procedure volumes decreased by 10% due to COVID-19, the company expects to achieve further regulatory approvals in 2021, including CE Mark for its Intelligent Surgical Unit.
TransEnterix, Inc. (NYSE American: TRXC) announced that CEO Anthony Fernando and CFO Shameze Rampertab will speak at two upcoming virtual investor conferences. The presentations include:
- H.C. Wainwright BioConnect 2021 Conference on-demand from January 11, 2021, at 6:00 AM ET.
- Digital Surgery Panel at Westwicke/ICR Conference on January 14, 2021, at 10:00 AM ET.
- Presentation at Westwicke/ICR Conference on January 14, 2021, at 3:15 PM ET.
Webcasts are accessible on the company’s investor relations page for 90 days.
TransEnterix, Inc. (NYSE American: TRXC) announced a lease agreement for its Senhance® Surgical System with Southern Surgical Hospital in Slidell, Louisiana. This partnership aims to enhance minimally invasive surgery through digital assistance, improving patient care while managing healthcare costs. The Senhance System, which provides robotic precision and advanced instrumentation, is designed to meet laparoscopic standards. Southern Surgical Hospital boasts a CMS 5-star rating and is recognized for patient experience, aligning with TransEnterix's commitment to digital laparoscopy and innovative surgical technology.
TransEnterix, Inc. (NYSE American:TRXC) has received registration certification from Roszdravnadzor, allowing the Senhance® Surgical System to be sold and used throughout Russia. This approval marks a significant milestone for the company, as robotic surgery adoption in Russia has been limited due to high costs. The Senhance system aims to address these challenges by providing benefits like robotic precision and advanced instrumentation at lower per-procedure costs. TransEnterix has partnered with BOWA to enhance commercialization efforts in the CIS region, aiming to leverage this recent expansion into the largest CIS market.